¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"mass scattering power"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • mass miniature radiography
    Áý´Ü°£Á¢¹æ»ç¼±ÃÔ¿µ(¼ú), X¼±Áý´Ü°£Á¢°ËÁø
  • mass polymerization
    µ¢ÀÌÁßÇÕ
  • mass radiography
    Áý´Ü¹æ»ç¼±ÃÔ¿µ(¼ú), X¼±Áý´Ü°ËÁø
  • mass reflex
    Áý´Ü¹Ý»ç
  • mass screening
    Áý´Ü¼±º°°Ë»ç
  • mass spectrograph
    Áú·®ºÐ±¤»çÁø±â, Áú·®ºÐ¼®±â
  • mass spectrography
    Áú·®ºÐ±¤ºÐ¼®(¹ý)
  • mass spectrometer
    Áú·®ºÐ±¤°è
  • mass treatment
    Áý´ÜÄ¡·á
  • polypoid mass
    Æú¸³¸ð¾çµ¢ÀÌ, Æú¸³¸ð¾çÁ¾±«
  • sonolucent mass
    ÃÊÀ½ÆÄÅõ°úÁ¾±«
  • selective mass chemotherapy
    ¼±ÅÃÁý´ÜÈ­Çпä¹ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • lateral mass
    °¡Âʵ¢ÀÌ
  • lean body mass
    ¸¶¸¥Ã¼Áß, Á¦Áö¹æÃ¼Áß
  • mass lesion
    µ¢À̺´ÅÍ
  • mass ligature
    Áý´Ü¹­±â
  • mass
    µ¢ÀÌ, µ¢¾î¸®, Áý´Ü, Áú·®
  • mass measurement
    Áú·®ÃøÁ¤
  • mass movement
    Áý´Ü¿îµ¿
  • mass polymerization
    µ¢ÀÌÁßÇÕ
  • mass radiography
    Áý´Ü¹æ»ç¼±ÃÔ¿µ¼ú, ¿¢½º¼±Áý´Ü°ËÁø
  • mass reflex
    Áý´Ü¹Ý»ç
  • mass screening
    Áý´Ü°Ë»ç
  • mass spectrograph
    Áú·®ºÐ±¤»çÁø±â
  • mass spectrography
    Áú·®ºÐ±¤°èÃø¹ý
  • mass spectrometer
    Áú·®ºÐ±¤°è
  • mass susceptibility
    Áú·®¹Î°¨µµ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • rotatory power
    ¼±±¤µµ(àÁÎÃöô).
  • speech power
    À½¼º(ëåá¢)ÆÄ¿ì¾î.
  • speech power
    À½¼ºÅ©±â
  • stopping power
    ÀúÁö·Â
  • stopping power ratio
    ÀúÁö´Éºñ
  • transmit power
    Åõ°ú·Â
  • ultrasonic power
    ÃÊÀ½ÆÄ Ãâ·Â (õ±ëå÷î õóÕô)
  • vergence power
    ÀÌÇâ¿îµ¿·Â
  • vertex power
    Á¤Á¡±¼Àý·Â
  • water containing power
    Èí¼ö·Â(ýåâ©æ³).
  • water power
    ¼ö·Â(ËàËç).
  • wetting power
    ½ÀÀ±·Â(ã¥ëÈæ³).
  • will to power
    ±Ç·Â¿¡·ÎÀÇ ÀÇÁö(ëòò¤).
  • working power
    ³ë·Â·Â(ËÈËçËç).
  • achromatic mass
    ¹«»öÁú.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
LPF leukocytosis-promoting factor; leukopenia factor; lipopolysaccharide factor; localized plaque format...
lpf low-power field
MAP malignant atrophic papulosis; mandibular angle plane; maturation-activated protein; maximal aerobic ...
MMP matrix metalloproteinase; muscle mechanical power
MPF maturation promoting factor; mean power frequency
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
MAP Maximal Aerobic Power
MP Mean Power
MPF Mean Power Frequency
NPS Noise Power Spectrum
NPP Nuclear Power Plant
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
molar mass See: molecular weight.
(05 Mar 2000)
molecular mass The sum of the atomic weight's of all the atoms constituting a molecule; the mass of a molecule relative to the mass of a standard atom, now 12C (taken as 12.000). Relative molecular mass (Mr) is the mass relative to the dalton and has no units.
See: atomic weight.
Synonym: molecular mass, molecular weight ratio, relative molecular mass.
(05 Mar 2000)
pill mass The mixture of drug(s), excipients, diluents and binders with a suitable amount of liquid to form a plastic mass which can be rolled into a long rod and cut into the appropriate number of units for pills to be rolled from.
Synonym: pill mass.
(05 Mar 2000)
pilular mass The mixture of drug(s), excipients, diluents and binders with a suitable amount of liquid to form a plastic mass which can be rolled into a long rod and cut into the appropriate number of units for pills to be rolled from.
Synonym: pill mass.
(05 Mar 2000)
complex liver mass in kids <radiology> Epithelial, FNH (uncommon, F greater than M), hepatic adenoma (uncommon, F greater than M), hepatoma (increased aFP in 90%), hepatoblastoma (increased aFP, less than 2 years of age), mesenchymal, hamartoma, cavernous haemangioma, haemangioendothelioma, embryonal rhabdomyosarcoma (obstructs common bile duct; less than 5 years of age), undifferentiated sarcoma, teratoma, abscess / haematoma / complicated cyst
(12 Dec 1998)
critical mass <chemistry, radiobiology> The minimum amount of mass of a combination of radioactive substances needed for the substances to generate and lose an exactly balanced number of neutrons to make a chain reaction which will keep going by itself.
(09 Oct 1997)
posterior mediastinal mass <radiology> Mnemonic: HALOVEEN, haematoma, abscess, lymph nodexs, osteophyte, vertebral (metastasis, plasmacytoma), extramedullary haematopoesis, oesophagus, neurogenic
(12 Dec 1998)
cystic pelvic mass <radiology> Physiologic ovarian cyst, The Big Three (ectopic, PID, endometriosis), ovarian neoplasm, nongynecologic mass
(12 Dec 1998)
cystic sellar mass <radiology> Arachnoid cyst, cystic craniopharyngioma, dermoid / epidermoid
(12 Dec 1998)
sclerotic cemental mass Benign fibro-osseous jaw lesions of unknown aetiology, occurring predominantly in middle-aged black females, which present as large painless radiopaque masses usually involving several quadrants of the jaw.
Synonym: florid osseous dysplasia, cemental dysplasia.
(05 Mar 2000)
solid renal mass <radiology> MALIGNANT until proven otherwise!, renal cell carcinoma (85%), other malignancy (10%), renal sarcoma, lymphoma, transitional cell carcinoma, metastases, benign mass (5%), oncocytoma, angiomyolipoma (fat present), fibroma
(12 Dec 1998)
solitary echogenic liver mass <radiology> Haemangioma, focal fatty infiltration, hepatoma, adenoma, focal nodular hyperplasia, hepatic lipoma
(12 Dec 1998)
spectrometry, mass, fast atom bombardment A mass spectrometric technique that is used for the analysis of a wide range of biomolecules, such as glycoalkaloids, glycoproteins, polysaccharides, and peptides. Positive and negative fast atom bombardment spectra are recorded on a mass spectrometer fitted with an atom gun with xenon as the customary beam. The mass spectra obtained contain molecular weight recognition as well as sequence information.
(12 Dec 1998)
spectrometry, mass, matrix-assisted laser desorption-ionization A mass spectrometric technique that is used for the analysis of large biomolecules. Analyte molecules are embedded in an excess matrix of small organic molecules that show a high resonant absorption at the laser wavelength used. The matrix absorbs the laser energy, thus inducing a soft disintegration of the sample-matrix mixture into free (gas phase) matrix and analyte molecules and molecular ions. In general, only molecular ions of the analyte molecules are produced, and almost no fragmentation occurs. This makes the method well suited for molecular weight determinations and mixture analysis.
(12 Dec 1998)
spectrometry, mass, secondary ion A mass-spectrometric technique that is used for microscopic chemical analysis. A beam of primary ions with an energy of 5-20 kiloelectronvolts (kev) bombards a small spot on the surface of the sample under ultra-high vacuum conditions. Positive and negative secondary ions sputtered from the surface are analyzed in a mass spectrometer in regards to their mass-to-charge ratio.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • fluid power
    À¯Ã¼µ¿·Â
  • geothermal power generation
    Áö¿­¹ßÀü(Áö¿­·Î ºÐÃâÇÏ´Â Áõ±â,¿­¼ö¸¦ ÀÌ¿ëÇÏ´Â ¹ßÀü) oY
  • giant power
    ´ÙÀ̳ʸ¶ÀÌÆ®ÀÇ ÀÏÁ¾
  • gray power
    ³ëÀÎ ÆÄ¿ö
  • green power
    ±Ý·Â;Àç·Â
  • human power
    ÀÎÀû ÀÚ¿ø
  • magnifying power
    ¹èÀ²
  • man power
    ÀηÂ(°ø·üÀÇ ´ÜÀ§·Î 1/10¸¶·Â)
  • man power
    ÀÎÀû ÀÚ¿ø;ÀηÂ
  • motive power
    ¿øµ¿·Â;±â°üÂ÷
  • nuclear power
    (µ¿·ÂÀ¸·Î¼­ÀÇ)¿øÀÚ·Â;ÇÙ¹«±â º¸À¯±¹
  • power
    Èû;´É·Â;Àç´É;ü·Â;¼¼·Â;±Ç·Â;Áö¹è·Â;Á¤±ÇÀ¯·ÂÀÚ;°­±¹;°ÅµìÁ¦°ö;ÀÛ¾÷·ü;°ø·ü;µ¿·Â;È®´ë·Â;½Å(a power of ¸¹Àº,in one's power ÈûÀÌ ¹ÌÄ¡´Â ¹üÀ§³»¿¡,Áö¹èÇÏ¿¡)
  • power base
    ¼¼·Â ±â¹Ý;ÁöÁö ¸ðü
  • power boat
    ¹ßµ¿±â¼±;¸ðÅÍ º¸Æ®
  • power brake
    µ¿·Âºê·¹ÀÌÅ©
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á